Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
861-880 of 2,120 trials

Heart Attack Treatment: RTP-026 Study

We are exploring a new medication, RTP-026, for patients who have had a heart attack. The study will assess its safety and effectiveness compared to a placebo.

Heart Attack (Acute Myocardial Infarction)1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Kidney Function: Vonafexor Study

We are studying the effects of vonafexor on kidney function in people with impaired renal function and suspected MASH. The trial will help us understand how different doses impact kidney health and safety.

Impaired Renal Function and Suspected MASH6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Thyroid Eye Disease: Efgartigimod PH20 SC

We are studying a new treatment for adults with thyroid eye disease to see if it reduces eye bulging compared to a placebo. This trial will help us understand its effectiveness and safety.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

Thyroid Eye Disease: Efgartigimod PH20 SC Study

We are testing a new treatment called efgartigimod PH20 SC in adults with thyroid eye disease. The goal is to see if it works better than a placebo in reducing symptoms.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

BRAF-V600E Mutant Metastatic Colorectal Cancer: BRAVE Trial

We are studying a combination of encorafenib, cetuximab, and bevacizumab for patients with BRAF-V600E mutated metastatic colorectal cancer who have not responded to previous treatments. The trial aims to evaluate the safety and effectiveness of this treatment approach.

Metastatic Colorectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: CD19 CAR-T Cell Therapy

We are studying the safety of a new CAR-T cell treatment for patients with refractory acute myeloid leukemia. This trial aims to see how well the treatment works and how long the CAR-T cells last in the body.

Recurrent Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Fast-Acting Insulins and Their Post-Meal Effects in Type 1 Diabetes

We are studying how different fast-acting insulins affect blood sugar levels after meals in people with type 1 diabetes. This research may help identify the best insulin for managing glucose and reducing oxidative stress.

Type 1 Diabetes1-2 yearsSafety phase (I)No PlaceboStandard MedicinesDiabetologyEndocrinology

Non-Small Cell Lung Cancer: New Treatment Combinations with Pembrolizumab

We are studying new investigational treatments combined with pembrolizumab and chemotherapy for patients with newly diagnosed resectable non-small cell lung cancer. The goal is to see how well these combinations work and their safety before surgery.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)Investigational MedicinesOncology

MOG Antibody-Associated Disease: Rozanolixizumab Study

We are studying whether Rozanolixizumab is effective and safe for adults with MOG antibody-associated disease. This research aims to provide insights into a potential new treatment for this condition.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurology

Indolent Non-Hodgkin's Lymphoma: EO2463 Cancer Vaccine

We are investigating a new cancer vaccine, EO2463, for patients with indolent Non-Hodgkin's Lymphoma. The trial aims to assess its safety and effectiveness alone and with other treatments.

Indolent Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: BEAM-302 Treatment Study

We are exploring a new treatment for adults with Alpha-1 Antitrypsin Deficiency-related lung or liver disease. The study aims to evaluate its safety and effectiveness in improving health outcomes.

Alpha-1 Antitrypsin Deficiency (AATD)>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyPulmonology

Melanoma Treatment: Nivolumab with Isolated Limb Perfusion

We are studying whether combining nivolumab with isolated limb perfusion helps patients with in-transit melanoma metastases achieve better treatment responses. This trial will also look at safety and quality of life.

In-transit Metastasis of Malignant Melanoma1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteDermatologyOncology

Heart Attack Treatment: EVOLocumab Study

We are studying whether adding evolocumab to standard cholesterol management helps reduce serious heart-related events in patients recently hospitalized for a heart attack. This trial aims to improve outcomes for those affected by acute myocardial infarction.

High Cholesterol>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Relapsing Multiple Sclerosis: Remibrutinib vs. Ocrelizumab

We are studying whether remibrutinib is as effective and safe as ocrelizumab for people with relapsing multiple sclerosis after switching treatments. This trial will help us understand the best options for managing the disease.

Relapsing Multiple SclerosisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNeurology

Lobular Breast Cancer: Capivasertib and Fulvestrant Study

We are studying a new treatment combination for patients with high-risk lobular breast cancer to see if it improves cancer control and safety compared to standard therapy.

Invasive Lobular Breast Carcinoma≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Late-Onset Pompe Disease: SPK-3006 Infusion Study

We are testing a new intravenous treatment for adults with late-onset Pompe disease to evaluate its safety and potential benefits. This study will help us understand how well the treatment works and how it is tolerated.

Pompe Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterologyHematologyNeurology

Gastroesophageal Adenocarcinoma: MK-2870 with Pembrolizumab and Chemotherapy

We are studying a new treatment combination for patients with advanced gastroesophageal adenocarcinoma. The goal is to evaluate its safety and how well it may help manage the disease.

Gastroesophageal CancerSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesOncology

Lupus Nephritis: LNP023 Treatment Study

We are studying the safety and effectiveness of LNP023 in adults with active lupus nephritis. The goal is to see if it helps improve kidney function compared to standard treatments.

Lupus Nephritis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNephrologyRheumatology

Gastro-Enteropancreatic Neuroendocrine Tumors: RYZ101 Treatment

We are studying a new treatment, RYZ101, for patients with advanced GEP-NETs that have progressed after previous therapy. The trial compares RYZ101 to standard care to see if it improves patient outcomes.

Gastroenteropancreatic Neuroendocrine TumorsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Systemic Sclerosis-Related Lung Disease: Belimumab Study

We are investigating the long-term safety and effects of belimumab in adults with lung disease linked to systemic sclerosis. This study aims to see how the treatment impacts lung function and overall tolerability.

Lung Involvement in Systemic SclerosisBronchial Diseases>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPulmonologyRheumatology